# US 2010/0166859 A1 · Novel nutraceutical compositions and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166859 A1
- Document ID: US20100166859A1
- Status: Published application
- Kind: A1
- Application number: 12/160,823
- Filed: 2006-12-29
- Published: 2010-07-01
- Earliest claimed: 2006-01-16
- Inventors: Luppo Edens; Regina Goralczyk; Adrian Wyss
- Web page: https://patentgrep.com/patent/US20100166859A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A23L 33/18: Peptides; Protein hydrolysates
- A61K 38/06: Tripeptides
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a novel nutraceutical composition containing at least one tripeptide as active ingredient. The term “nutraceutical' as used herein denotes a usefulness in both the nutritional and pharmaceutical field of application. Thus, the novel nutraceutical compositions can find use as supplement to food and beverages, and as pharmaceutical formulations for enteral or parenteral application which may be solid formulations such as capsules or tablets, or liquid formulations, such as solutions or suspensions. As will he evident from the foregoing, the term nutraceutical composition also comprises food and beverages containing the above-specified active ingredients, for example protein hydrolysates which are rich in tripeptides according to the invention. The compositions are useful to improve cognitive functions such as learning, memory and alertness and for the treatment of a disorder connected to impaired neurotransmission and of conditions resulting from hypoxia and for alleviating neuropathic pain.

## Claims

### Claim 1

Nutraceutical composition comprising as the active ingredient at least one tripeptide encompassed by the general formula
a salt, derivative, metabolite or analogue thereof, wherein
R1 represents a residue derived from amino acids Gly (G) or Pro (P) and
R2 independently represents a residue derived from any of the amino acids Gly (G), Glu (E), Pro (P), Cys (C), Asp (D), Phe (F), His (H), Ser (S), Gln (Q), Arg (R), Thr (T), or
the N-terminal amino acid is Pyroglutamate.

### Claim 2 (depends on 1)

Composition according to claim 1 containing at least one, preferably two of the following tripeptides: EPP, PPP, SPP, DGP, GGP, HGP, PyroglutamatePP which interacts with the glycine site of the NMDA receptor and/or the with the AMPA receptor.

### Claim 3 (depends on 1)

Composition according to claim 1 containing at least GGP and EPP as active ingredients.

### Claim 4 (depends on 1)

Composition according to claim 1 containing as active ingredients at least one of the following combinations:
GGP and DGP and/or EGP and/or FGP and/or HGP and/or IGP and/or PGP and/or QGP and/or RGP and/or SGP and/or TGP and/or VGP and/or DPP and/or FPP and/or GPP and/or HPP and/or PPP and/or SPP; EPP and CPP and/or PPP and/or SPP and/or DGP and/or HGP.

### Claim 5 (depends on 1)

Composition according to claim 1, which comprises a proteinhydrolysate containing as major fraction at least one active ingredient as defined above.

### Claim 6 (depends on 1)

Composition according to claim 1, containing the at least one, preferably at least two tripeptides in an amount sufficient to administer to a human adult (weighing about 70 kg) a dosage from about 70 mg/day to about 1000 mg/day, preferably from about 70 mg/day to about 500 mg/day.

### Claim 7 (depends on 1)

Composition according to claim 1 being in form of food such as dairy products (yoghurts), in form of fortified food such as cereal bars and bakery items such as cakes and cookies, in form of dietary supplements such as tablets, pills, granules, dragées, capsules, and effervescent formulations, in form of non-alcoholic drinks such as soft drinks, sport drinks, fruit juices, lemonades, teas and milk based drinks, in form of liquid food such as soups and dairy products.

### Claim 8

The use of a at least one tripeptide encompassed by the general formula
a salt, derivative, metabolite or analogue thereof, wherein
R1 represents a residue derived from amino acids Gly (G) or Pro (P) and
R2 indepently represents a residue derived from any of the amino acids Gly (G), Glu (E), Pro (P), Cys (C), Asp (D), Phe (F), His (H), Ser (S), Gln (Q), Arg (R), Thr (T); or
the N-terminal amino acid is Pyroglutamate,
in the manufacture of a nutraceutical composition.

### Claim 9 (depends on 8)

The use as in claim 8 wherein the nutraceutical composition is a composition containing at least one, preferably two of the following tripeptides: EPP, PPP, SPP, DGP, GGP, HGP, PyroglutamatePP which interacts with the glycine site of the NMDA receptor and/or the with the AMPA receptor.

### Claim 10 (depends on 8)

The use as in claim 8 wherein the nutraceutical composition is intended to improve cognitive functions such as learning, memory and alertness.

### Claim 11 (depends on 8)

The use as in claim 8 for the manufacture of a composition for the treatment of a disorder connected to impaired neurotransmission.

### Claim 12 (depends on 11)

The use according to claim 11, wherein the composition is an antidepressant, a mood improver, a stress reliever, a condition improver.

### Claim 13 (depends on 8)

The use as in claim 8 wherein the nutraceutical composition is a pharmaceutical composition.

### Claim 14

A method to improve cognitive functions such as learning, memory and alertness in an animal including human, comprising administering an effective dose of at least one tripeptide or salt thereof having a general formula.
wherein
R1 represents a residue derived from amino acids Gly (G) or Pro (P) and
R2 indepently represents a residue derived from any of the amino acids Gly (G), Glu (E), Pro (P), Cys (C), Asp (D), Phe (F), His (H), Leu (I), Ser (S), Gin (Q), Arg (R), Thr (T), Val (V) or
the N-terminal amino acid is Pyroglutamate.

### Claim 15

A method for the treatment of a disorder connected to impaired neurotransmission in animals including humans, said method comprising administering to the patient an effective dose of at least one tripeptide or salt thereof having a general formula.
wherein
R1 represents a residue derived from amino acids Gly (G) or Pro (P) and
R2 indepently represents a residue derived from any of the amino acids Gly (G), Glu (E), Pro (P), Cys (C), Asp (D), Phe (F), His (H), Leu (I), Ser (S), Gln (Q), Arg (R), Thr (T), Val (V) or
the N-terminal amino acid is Pyroglutamate.

### Claim 16 (depends on 14)

The method of claim 14, wherein the tripeptide is selected from the group consisting of EPP, PPP, SPP, DGP, GGP, HGP, PyroglutamatePP.
